Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis

Inclusion Criteria: All patients affiliated to the French social security system will be eligible, after signing a consent form, and presenting the following criteria * Introduction within the last 3 months of at least one of the following ICIs: nivolumab, pembrolizumab, cemiplimab, avelumab, atezolizumab, ipilimumab, tremelimumab, durvalumab. * Suspicion of myocarditis defined by the presence of at least one of the following criteria adapted from the European Society of Cardiology guidelines: * Symptomatic patients (chest pain, dyspnea, palpitations, syncope/lipothymia) within 7 days of ICI administration * New ECG abnormality (ST-segment elevation, ST-segment undershift, arrhythmia, conductive disturbances, T-wave inversion) * Elevation of troponin above the 99th percentile of the laboratory reference value or, if troponin is already elevated before treatment, an increase of more than 30% of the baseline value * Recent LVEF decline or recent LV contraction abnormality on a TTE * Patient has given no objection Translated with www.DeepL.com/Translator (free version) Exclusion Criteria: * Age \<18 years * Major under guardianship or curatorship * Pregnant or breastfeeding women * Patient not covered by a social security plan * Hemodynamic or rhythmic instability * Estimation of glomerular filtration rate by the MDRD formula \<30ml/min/1.73m2 * Implantable equipment that does not allow for cMRI